适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Xentria Inc.
- 入组人数
- 225
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Randomized, Open-label, Single-Dose, Two-treatment, Two-period, Cross-over, Pivotal Bioequivalence Study Comparing Amoxicilin/Clavulanic acid powder for oral suspension 600 mg/42.9 mg/5 mL to Augemntin ES 600 mg/42.9 mg/5 mL powder for oral suspension in Healthy Adult Male and Female Volunteers under Fed Conditions.CTIS2023-503233-22-00Tarchominskie Zaklady Farmaceutyczne Polfa S.A.56
进行中（未招募）
1 期
A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects with Advanced MalignanciesAdvanced MalignanciesMedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104CTIS2024-514010-12-00Invox Pharma Limited131
招募中
1 期
Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM534 Administered Intravenously to Patients with Advanced Solid TumorsAdvanced Solid TumorsCTIS2024-513056-15-00Pharma Mar S.A.30
进行中（未招募）
1 期
A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of ABBV-383 in patients with relapsed or refractory Multiple MyelomaCTIS2023-507901-32-00AbbVie Deutschland GmbH & Co. KG55
招募中
1 期
Dose escalation trial of BNT152+153 in patients with cancerVarious solid tumors that are metastatic or unresectableMedDRA version: 20.0Level: LLTClassification code: 10025648Term: Malignant mast cell tumors unspecified site extranodal and solid organ sites Class: 10029104CTIS2023-509508-13-00BioNTech SE4